May 14, 2026 04:05PM
Apr 20, 2026 07:51AM
Apr 20, 2026 07:50AM
Mar 25, 2026 07:31AM
Mar 25, 2026 07:31AM
Mar 18, 2026 07:43AM
Mar 18, 2026 07:41AM Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Feb 24, 2026 08:02AM
Feb 24, 2026 08:00AM
Dec 3, 2025 08:30AM
Dec 3, 2025 08:30AM
Nov 12, 2025 08:00AM
Oct 15, 2025 09:15AM
Oct 15, 2025 09:15AM Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
Sep 29, 2025 08:30AM
Sep 29, 2025 08:30AM
Sep 3, 2025 11:33AM
Sep 3, 2025 11:33AM
Sep 3, 2025 08:45AM
Sep 3, 2025 08:45AM
Aug 13, 2025 08:00AM Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Aug 11, 2025 09:15AM
Aug 11, 2025 09:15AM
May 13, 2025 08:00AM
Mar 31, 2025 08:30AM
Mar 3, 2025 08:00AM
Feb 14, 2025 09:00AM
Feb 14, 2025 09:00AM Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
Jan 13, 2025 09:00AM
Dec 9, 2024 09:15AM
Dec 9, 2024 09:15AM
Nov 18, 2024 08:30AM
Nov 13, 2024 08:30AM
Nov 12, 2024 08:00AM
Nov 5, 2024 08:30AM Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Aug 13, 2024 08:00AM
Jul 15, 2024 08:31AM
Jul 15, 2024 08:30AM
Jul 2, 2024 09:00AM
Jul 1, 2024 09:00AM
Jun 4, 2024 08:30AM
May 29, 2024 08:32AM Artelo Biosciences (ARTL) Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
May 29, 2024 08:30AM
May 13, 2024 08:00AM
Apr 23, 2024 08:32AM
Apr 23, 2024 08:30AM
Mar 25, 2024 08:00AM
Jan 23, 2024 08:32AM
Jan 23, 2024 08:30AM Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Jan 8, 2024 08:30AM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All